Description: Kyowa Hakko Kirin Co., Ltd., a research and development-based life sciences company, manufactures and markets pharmaceuticals and bio-chemicals worldwide. Its products include ABSTRAL, a novel sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia. The company's products also comprise LEUNASE for acute lymphoblastic leukemia; Mitomycin-C, an anticancer antibiotic; Moventig for the treatment of opioid induced constipation in adult patients; PecFent, a nasally administrated spray; and REGPARA, a new class of agent for the treatment of secondary hyperparathyroidism. In addition, it offers Romiplate/Nplate, a genetically recombinant protein, which stimulates platelet production through the stimulation of thrombopoietin receptors; and SANCUSO for the treatment for nausea and vomiting. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Hakko Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
Home Page: www.kyowakirin.com
Otemachi Financial City Grand Cube
Tokyo,
100-0004
Japan
Phone:
81 3 5205 7200
Officers
| Name | Title |
|---|---|
| Mr. Masashi Miyamoto Ph.D. | Pres, CEO & Representative Director |
| Mr. Motohiko Kawaguchi | CFO & Head of Global Fin. |
| Mr. Yutaka Osawa M.B.A. | CCO & Representative Director |
| Satoko Yoshida | Head of Global Corp. Communications |
| Hiroshi Sonekawa | Head of Japan Sales & Marketing |
| Wataru Murata M.B.A. | Head of Global HR |
| Dr. Toshifumi Mikayama Ph.D. | Chief International Bus. Officer & Director |
| Takeyoshi Yamashita Ph.D. | Chief Strategy Officer |
| Yasuo Fujii M.B.A. | Head of Global Bus. Devel. |
| Jean-David Rafizadeh-Kabe J.D., M.D. | Head of Global Pharmacovigilance |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 25.1889 |
|---|---|
| Trailing PE: | 22.9732 |
| Price-to-Book MRQ: | 2.1809 |
| Price-to-Sales TTM: | 0.0322 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5752 |